Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.”
Auris Medical is a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. The company has two lead clinical-stage product candidates, (i) Keyzilen (AM-101), which is being developed for the treatment of acute inner ear tinnitus and (ii) AM-111, which is being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and fast track designation by the FDA. AM-125 is being developed for the treatment of vertigo. In addition, the company is pursuing early stage projects for the treatment of tinnitus. The company was founded in 2003 and is headquartered in Zug, Switzerland.
The Davis Polk capital markets team included partner Sophia Hudson and associates Pedro J. Bermeo, Jaryn S. Fields and Amarilice C. Young. The tax team included partner William A. Curran. Associate Huiyu Yin provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.